Watchdog recommends Price subpoena in stock sales probe

Watchdog recommends Price subpoena in stock sales probe
© Getty Images

A congressional watchdog is recommending the subpoena of former Health and Human Services Secretary Tom PriceThomas (Tom) Edmunds PriceWhite House officials discussing potential replacements for FEMA chief: report Overnight Health Care: CBO finds bill delaying parts of ObamaCare costs B | Drug CEO defends 400 percent price hike | HHS declares health emergency ahead of hurricane HHS should look into Azar's close ties to the drug industry MORE after he refused to cooperate in its probe of Rep. Chris CollinsChristopher (Chris) Carl CollinsThe Hill's Morning Report — Sponsored by United Against Nuclear Iran — Kavanaugh, accuser say they’re prepared to testify Indicted lawmaker angers GOP with decision to run for reelection Election Countdown: Trump confident about midterms in Hill.TV interview | Kavanaugh controversy tests candidates | Sanders, Warren ponder if both can run | Super PACs spending big | Two states open general election voting Friday | Latest Senate polls MORE (R-N.Y.) related to stock sales of an Australian biotechnology firm.

The Office of Congressional Ethics (OCE) on Thursday said Price was one of 10 individuals or entities that refused to cooperate with the investigation into whether Collins improperly shared nonpublic information in the purchase of Innate Immunotherapeutics Limited stocks.

Collins sits on Innate’s board and is the company’s largest shareholder.

In its report, the watchdog said there is "substantial reason to believe" Collins violated federal law and House rules, recommending the House Ethics Committee probe the claims.

OCE, an independent entity that reviews allegations against House members, also advised issuing a subpoena for Price to determine what he knew about the stocks.

Innate said it sold nearly $1 million in stock in discounted shares to Price while he was still a congressman, according to a Wall Street Journal report.

ADVERTISEMENT

Price came under fire during his confirmation hearings for stock trades made while he was involved in health-care legislation as a member of Congress.

Price defended his stock trades in the hearings and denied wrongdoing.

Democrats said he could have broken insider trading laws or a law against trading on congressional knowledge.

Price sold his shares of Innate in February, earning at least $225,000 on a $94,000 investment, according to congressional disclosure forms. The sales were made to comply with the ethics agreement he signed when he became the Health secretary.

Price resigned as Health secretary late last month after intense criticism of his use of private jets for professional trips at taxpayer expense, reportedly racking up more than $1 million in flights in just eight months.